Ripretinib usage and dosage in the treatment of stromal tumors

Ripretinib is used to treat adult patients with advanced gastrointestinal stromal tumors (GIST). The recommended dose in the drug instructions is 150 mg once daily until disease progression or unacceptable toxicity occurs. If patients experience adverse reactions during treatment with repetinib, the dose can be reduced to 100 mg orally once daily. Patients who cannot tolerate 100 mg orally once daily should permanently discontinue repetinib. Patients need to take the drug under the guidance and supervision of a doctor. If it is less than 8 hours since the missed scheduled dose, it is recommended that the patient take the missed dose. If a patient experiences vomiting after taking repetinib, do not take additional doses but continue with the next scheduled dose.